Evaluation of the effects of melatonin supplementation in patients with type 2 diabetes
Phase 3
- Conditions
- E16.1OtherDiabetic nephropathy.Chapter IV Endocrine, nutritional and metabolic diseases(E00-E90)
- Registration Number
- IRCT20230212057393N3
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 38
Inclusion Criteria
All patients with type 2 diabetes whose nephropathy was diagnosed through ACR test (>30 mg/gr) during a three-month period
Exclusion Criteria
Patients with heart failure
Pregnant mothers
Lactating mothers
Sensitivity to melatonin and its analogues and simultaneous use of interfering drugs such as fluvoxamine,...
Patients with urinary tract infections and uncontrolled blood pressure
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of the nephroprotective effect of melatonin in patients with diabetic nephropathy. Timepoint: At the beginning of the study, before the intervention and at the end of the work after 3 months, ACR, serum creatinine and sugar of the patients are evaluated by a certain laboratory of the effect of oral melatonin drug. Method of measurement: The effect of melatonin drug on diabetic nephropathy patients is evaluated by using standard laboratory values and laboratory results.
- Secondary Outcome Measures
Name Time Method Creatine-fasting blood sugar-glomerular filtration. Timepoint: 3 month. Method of measurement: laboratory test.